## BioAge's BGE-102 Pill Shows 86% Inflammation Drop in Early Heart Risk Trial
BioAge Labs has reported a significant anti-inflammatory effect from its experimental oral drug, BGE-102, in an early-stage clinical trial. In a Phase 1 study of obese patients with elevated inflammation, a 60-milligram dose reduced levels of high-sensitivity C-reactive protein (hs-CRP)—a key biomarker linked to cardiovascular risk—by 86% after three weeks. This reduction matches the effect previously seen with a higher 120-mg dose, suggesting a potent and potentially dose-efficient mechanism.

The data indicates that 87% of patients on the 60-mg dose achieved hs-CRP levels below 2 mg/liter, a threshold associated with lower risk of heart complications. This result places BioAge among a growing cohort of drug developers targeting systemic inflammation as a root cause of chronic diseases, moving beyond traditional symptom management. The pill's performance in this initial safety and biomarker study provides a concrete signal for its potential in cardiovascular risk prevention.

The findings intensify the strategic race to develop oral anti-inflammatory therapies for cardiometabolic conditions. While still early-stage, the pronounced biomarker response positions BGE-102 as a candidate to watch, applying pressure on the broader field to validate inflammation as a treatable pathway for heart disease. Success in later-phase trials could reshape preventive cardiology, but the path forward remains dependent on demonstrating actual clinical outcomes, not just biomarker changes.
---
- **Source**: STAT News
- **Sector**: The Lab
- **Tags**: clinical trial, cardiovascular disease, inflammation, biotech, Phase 1
- **Credibility**: unverified
- **Published**: 2026-04-21 11:52:31
- **ID**: 74176
- **URL**: https://whisperx.ai/en/intel/74176